Skip to main content

Table 1 Patients' characteristics at diagnosis according to CK-19 mRNA-positive cells during follow-up

From: Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

Characteristics All Patients CK-19 mRNA-persistently negative CK-19 mRNA-persistently positive  
  N % N % N %  
Patients enrolled 312   80 25.6 99 31.7  
Age        Mann-Whitney
P = 0.197
median (range) 54 (26 to 77) 51.5 (26 to 75) 54 (28 to 75)  
Menopausal status        P = 0.372
Pre-menopausal 145 46.5 41 51.3 44 44.4  
Post-menopausal 167 53.5 39 48.8 55 55.6  
Tumor size        T2/T3 vs T1
T1 116 37.2 30 37.5 33 33.3 P = 0.637
T2 174 55.8 43 53.8 59 59.6  
T3 22 7.1 7 8.8 7 7.1  
Lymph nodes        P = 0.082
N0 107 34.3 33 41.3 28 28.3  
N1 to 3 119 38.1 29 36.3 35 35.4  
N > 3 86 27.6 18 22.5 36 36.4  
Histology grade        P = 0.746
1/2 159 51.0 39 48.8 56 56.6  
3 119 38.1 28 35.0 36 36.4  
lobular 34 10.9 13 16.3 7 7.1  
HR        P = 0.156
ER(-)/PR(-) 70 22.4 24 30.0 22 22.2  
Other 190 60.9 39 48.8 60 60.6  
Unknown 52 16.7 17 21.3 17 17.2  
HR and Her-2        P = 0.116
ER(-)/PR(-)/HER-2(-) 52 16.7 19 23.8 16 16.2  
Other 255 65.1 41 51.3 66 66.7  
Unknowm 57 18.3 20 25.0 17 17.2  
Radiation therapy        P = 0.937
No 24 7.7 7 8.8 9 9.1  
Yes 289 92.3 73 91.2 90 90.9  
Hormonotherapy        P = 0.103
No 23 7.4 10 12.5 5 5.1  
Yes 289 92.6 70 87.5 94 94.9  
Type of hormonotherapy        P = 0.119
No hormonotherapy 23 7.4 10 12.5 5 5.1  
AIs 33 10.6 10 12.5 11 11.1  
T 50 16.0 10 12.5 19 19.2  
AIs & T 57 18.3 9 11.3 22 22.2  
LHRH 32 10.3 11 13.8 8 8.1  
LHRH + T or AIs 117 37.5 30 37.5 34 34.3  
Chemotherapy        P = 0.011
CMF 30 9.6 11 13.8 4 4.0  
FEC 149 47.8 31 38.8 57 57.6  
T/EC 133 42.6 38 47.5 38 38.4  
  1. AIs, aromatase inhibitors; CMF, cyclophosphamide-methotraxate-fluorouracil; FEC, fluorouracil-epirubicin-cyclophosphamide; HR, hormone receptor; LHRH, luteinizing-hormone-releasing hormone; T, tamoxifen; T/EC, taxane/epirubicin-cyclophosphamide.